CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancerGerard Walls, Alastair Greystoke, Stephen Harrow et al.|Clinical and Translational Radiation Oncology|2020Cited by 34
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah Buckley, Naveen Vasudev, Fiona Collinson et al.|BMC Cancer|2019Cited by 17
Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physiciansMałgorzata Krajnik, Sabina Panfilak, Nilay Hepgul et al.|BMC Pulmonary Medicine|2022Cited by 15
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial resultsMatthew Winter, Janet E. Brown, Rob Coleman et al.|Journal of bone oncology|2022Cited by 10
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDEKatrina Walker, Samantha Hinsley, Rachel Phillip et al.|JCO Precision Oncology|2022Cited by 4